Clinical Trial Update: Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating pharmacokinetics and safety of MB-102 (Relmapirazin) and the MediBeacon transdermal GFR measurement system in normal and renal-impair…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• MB-102
• MediBeacon transdermal GFR measurement system

Snippet

Sponsor: MediBeacon | Conditions: Chronic Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2024-04-18